Suramin attenuates dystrophin‐deficient cardiomyopathy in the mdx mouse model of duchenne muscular dystrophy |
| |
Authors: | Drielen De Oliveira Moreira MSci Juliano Alves Pereira MSci Ana Paula Tiemi Taniguti DSci Cíntia Yuri Matsumura DSci Luis Alberto Ferreira Ramos MSci Miguel Arcanjo Areas PhD Humberto Santo Neto PhD Maria Julia Marques PhD |
| |
Affiliation: | Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, Universidade Estadual de Campinas (UNICAMP), , Campinas, SP, 13083‐970 Brazil |
| |
Abstract: | Introduction: The purpose of this study was to determine the effects of suramin, an antifibrotic agent, on cardiac function and remodeling in mdx mice. Methods: mdx mice (8 months old) received intraperitoneal injections of suramin twice a week for 3 months. Control mdx mice (8 months old) were injected with saline. Results: Suramin improved the electrocardiography profile with the main corrections seen in S‐ to R‐wave ratio, PR interval, and Q amplitude, and a significant decrease in the cardiomyopathy index. Suramin decreased myocardial fibrosis, inflammation, and myonecrosis. Conclusions: These findings suggest that suramin may be a new adjunctive therapy to help improve cardiomyopathy in DMD. Muscle Nerve 48 : 911–919, 2013 |
| |
Keywords: | antifibrotic drugs cardiomyopathy DMD mdx suramin |
|
|